NR4A1 and breast carcinoma: In this randomized phase III trial, ribociclib or placebo, each combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor, was investigated as first-line treatment in 627 pre- and perimenopausal women with hormone receptor (HR)-positive, human epidermal growth factor 2(HER2)-negative advanced breast cancer (ABC).